ClinicoEconomics and Outcomes Research最新文献

筛选
英文 中文
Actions to Improve the Secondary Prevention of Fragility Fractures in Women with Postmenopausal Osteoporosis: A Social Return on Investment (SROI) Study. 改善绝经后骨质疏松妇女脆性骨折二级预防的措施:一项社会投资回报(SROI)研究
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S480674
Francisco Jesús Olmo-Montes, José Ramón Caeiro-Rey, Pilar Peris, Verónica Pérez Del Río, Íñigo Etxebarria-Foronda, José Manuel Cancio-Trujillo, Teresa Pareja, Esteban Jódar, Antonio Naranjo, María Jesús Moro-Álvarez, Manuel García-Goñi, Josep Vergés, Stefano Maratia, Ignasi Campos Tapias, Miriam Prades, Susana Aceituno
{"title":"Actions to Improve the Secondary Prevention of Fragility Fractures in Women with Postmenopausal Osteoporosis: A Social Return on Investment (SROI) Study.","authors":"Francisco Jesús Olmo-Montes, José Ramón Caeiro-Rey, Pilar Peris, Verónica Pérez Del Río, Íñigo Etxebarria-Foronda, José Manuel Cancio-Trujillo, Teresa Pareja, Esteban Jódar, Antonio Naranjo, María Jesús Moro-Álvarez, Manuel García-Goñi, Josep Vergés, Stefano Maratia, Ignasi Campos Tapias, Miriam Prades, Susana Aceituno","doi":"10.2147/CEOR.S480674","DOIUrl":"10.2147/CEOR.S480674","url":null,"abstract":"<p><strong>Purpose: </strong>This study evaluates the Social Return on Investment (SROI) of implementing measures to prevent fragility fractures in postmenopausal women with osteoporosis (OP) in Spain.</p><p><strong>Methods: </strong>A group of 13 stakeholders identified necessary actions for improving refracture prevention and assessed the investment required from the Spanish National Health System (SNHS), considering direct, indirect, and intangible costs over a one-year period. Unitary costs were sourced from scientific literature and official data, and intangible costs were estimated through surveys on women's willingness to pay for better health-related quality of life. The SROI ratio was calculated from both a social perspective (including all returns) and the SNHS perspective (including only direct and intangible costs). A sensitivity analysis evaluated the returns in worst- and best-case scenarios over three years.</p><p><strong>Results: </strong>Stakeholders agreed on four main actions: 1) establishing fracture liaison services; 2) harmonizing clinical practice guidelines and provide training for healthcare professionals (HCPs); 3) promoting HCPs' adherence to fracture registries and 4) raising awareness of OP and fragility fractures. From the social perspective, implementing these actions would cost the SNHS €4,375,663 but yield a social return of €96,939,931 in the first year, resulting in a SROI ratio of €22.15 per euro invested (€28.69, 23.14, 24.29, and 10.70 for the four actions, respectively). From the SNHS perspective, the return would be €36,453,509 (€21,523,444 tangible), with a SROI of €8.33 (€4.92 tangible) and for the four actions: €9.99, 9.39, 8.45, and 3.79, respectively (€5.89, 5.54, 4.96 and 2.27 tangible). The investment would be lower than the return for all actions (3.49%, 4.32%, 4.12% and 9.34% of social perspective return, respectively) and scenarios.</p><p><strong>Conclusion: </strong>According to our SROI method, implementing different actions to improve secondary fracture prevention would achieve a considerable social benefit, which, in terms of direct, indirect, and intangible costs, would far outweigh the investment.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"889-901"},"PeriodicalIF":2.1,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11681784/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital. 土耳其一家私立医院心血管外科实施患者血液管理的预算影响分析
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-12-19 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S481565
Mehtap Tatar, Cansu Selcan Akdeniz, Utku Zeybey, Salih Şahin, Çavlan Çiftçi
{"title":"Budget Impact Analysis of Implementing Patient Blood Management in the Cardiovascular Surgery Department of a Turkish Private Hospital.","authors":"Mehtap Tatar, Cansu Selcan Akdeniz, Utku Zeybey, Salih Şahin, Çavlan Çiftçi","doi":"10.2147/CEOR.S481565","DOIUrl":"10.2147/CEOR.S481565","url":null,"abstract":"<p><strong>Purpose: </strong>In cardiovascular surgeries, iron deficiency anemia and transfusion of blood products are associated with mortality and morbidity, prolonged hospital stay and poor patient outcomes. Patient blood management (PBM) is a patient-centered approach based on a 'three pillar' model that promotes optimum use of blood and blood products to improve outcomes. This study assessed the potential budget impact of implementing PBM in patients undergoing elective cardiovascular surgery in a private hospital in Turkey.</p><p><strong>Methods: </strong>Two models were developed to estimate the hospital budget impact of PBM. The first model encompassed implementation of the first pillar of PBM, which proposes treatment of iron deficiency anemia before a surgical procedure. The second covered implementation of all three pillars of PBM. Budget impact was estimated from the number of avoided complications after treating iron deficiency anemia and reducing blood transfusions. Rates of complication (sepsis, myocardial infarction, renal failure and stroke) with and without PBM were taken from published meta-analyses. Data on 882 cardiovascular operations performed during 2020-2022 were taken from the Florence Nightingale Istanbul Hospital. The costs of treating complications were estimated by applying Turkish Social Security Institution prices to a healthcare resource utilization tool for each complication completed by experts.</p><p><strong>Results: </strong>Results from the budget impact analysis showed that, by implementing the first pillar of PBM, the department could have avoided 30 complications and saved 4,189,802 TRY. For the second model based on implementing all three pillars of PBM, 29 complications could have been avoided by reducing the number of transfusions, with budget savings of 6,174,434 TRY. Reducing the length of hospital stay could have enabled 137 additional operations in the given period.</p><p><strong>Conclusion: </strong>Implementation of PBM in patients undergoing elective cardiovascular surgery in private hospitals could be a budget-saving strategy in Turkey and may provide an opportunity to increase revenue.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"877-887"},"PeriodicalIF":2.1,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11668246/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142886296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China. 中国治疗前列腺癌的特普瑞林6个月制剂的资源利用评估和成本最小化分析。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-12-13 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S485856
Ying Chen, Jiahua Pan, Yan Zhong, Bin Wu, Mengxia Yan, Ruiyun Zhang
{"title":"Resources Utilization Assessment and Cost-Minimization Analysis of the 6-Monthly Formulation of Triptorelin in the Treatment of Prostate Cancer in China.","authors":"Ying Chen, Jiahua Pan, Yan Zhong, Bin Wu, Mengxia Yan, Ruiyun Zhang","doi":"10.2147/CEOR.S485856","DOIUrl":"10.2147/CEOR.S485856","url":null,"abstract":"<p><strong>Objective: </strong>Prostate Cancer can be treated with various formulations of Gonadotropin-Releasing Hormone Agonists (GnRHa), but cost analyses of these treatments in China are lacking. This study aims to evaluate the differences in cost and resource utilization between various formulations of GnRHa for Prostate Cancer by conducting a resource utilization assessment and cost minimization analysis.</p><p><strong>Methods: </strong>From the perspective of society and medical healthcare, this study used the cost minimization model to generate cost and resource estimates for GnRHa drug acquisition and administration for \"Current practice\" and for a \"Base case\" scenario. In the \"Base case\" scenario, all of the patients who were receiving 1-monthly or 3-monthly GnRHa therapy in \"Current practice\" switched to a 6-monthly formulation triptorelin. Cost/Resource estimates were calculated per patient per administration and scaled to annualized population levels. Deterministic sensitivity analysis was conducted to explore the uncertainty of the model variables and applied assumptions.</p><p><strong>Results: </strong>From a societal perspective, if all 1-monthly and 3-monthly formulations of GnRHa were switched to a 6-monthly formulation triptorelin, it is conservatively estimated that the annual societal cost could be reduced by ¥13,382,951.13, with an average annual cost savings of ¥46.53 per patient. Additionally, the 6-monthly formulation could save 3,608,973.91 hours annually, translating to an average time savings of 12.55 hours per patient, reducing treatment time by 78%. From a healthcare system perspective, if the introduction of the 6-monthly formulation of GnRHa is delayed, it would lead to an annual increase of ¥94 million in medical costs, and require an additional 64,445.96 working days for doctors and nurses. Deterministic sensitivity analysis demonstrated the model's robustness, showing the 6-monthly GnRHa remains cost-effective across various parameter changes, with drug price being the most influential factor.</p><p><strong>Conclusion: </strong>Compared to current 1-monthly and 3-monthly formulations, the 6-monthly GnRHa can reduce the total burden associated with prostate cancer treatment.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"869-875"},"PeriodicalIF":2.1,"publicationDate":"2024-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11651073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142847865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictive and Interpretable Machine Learning of Economic Burden: The Role of Chronic Conditions Among Elderly Patients with Incident Primary Merkel Cell Carcinoma (MCC). 经济负担的预测性和可解释性机器学习:慢性病在原发性梅克尔细胞癌(MCC)老年患者中的作用。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-12-11 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S456968
Yves Paul Vincent Mbous, Zasim Azhar Siddiqui, Murtuza Bharmal, Traci LeMasters, Joanna Kolodney, George A Kelley, Khalid M Kamal, Usha Sambamoorthi
{"title":"Predictive and Interpretable Machine Learning of Economic Burden: The Role of Chronic Conditions Among Elderly Patients with Incident Primary Merkel Cell Carcinoma (MCC).","authors":"Yves Paul Vincent Mbous, Zasim Azhar Siddiqui, Murtuza Bharmal, Traci LeMasters, Joanna Kolodney, George A Kelley, Khalid M Kamal, Usha Sambamoorthi","doi":"10.2147/CEOR.S456968","DOIUrl":"10.2147/CEOR.S456968","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate chronic conditions as leading predictors of economic burden over time among older adults with incident primary Merkel Cell Carcinoma (MCC) using machine learning methods.</p><p><strong>Methods: </strong>We used a retrospective cohort of older adults (age ≥ 67 years) diagnosed with MCC between 2009 and 2019. For these elderly MCC patients, we derived three phases (pre-diagnosis, during-treatment, and post-treatment) anchored around cancer diagnosis date. All three phases had 12 months baseline and 12-months follow-up periods. Chronic conditions were identified in baseline and follow-up periods, whereas annual total and out-of-pocket (OOP) healthcare expenditures were measured during the 12-month follow-up. XGBoost regression models and SHapley Additive exPlanations (SHAP) methods were used to identify leading predictors and their associations with economic burden.</p><p><strong>Results: </strong>Congestive heart failure (CHF), chronic kidney disease (CKD) and depression had the highest average incremental total expenditures during pre-diagnosis, treatment, and post-treatment phases, respectively ($25,004, $24,221, and $16,277 (CHF); $22,524, $19,350, $20,556 (CKD); and $21,645, $22,055, $18,350 (depression)), whereas the average incremental OOP expenditures during the same periods were $3703, $3,013, $2,442 (CHF); $2,457, $2,518, $2,914 (CKD); and $3,278, $2,322, $2,783 (depression). Except for hypertension and HIV, all chronic conditions had higher expenditures compared to those without the chronic conditions. Predictive models across each of phases of care indicated that CHF, CKD, and heart diseases were among the top 10 leading predictors; however, their feature importance ranking declined over time. Although depression was one of the leading drivers of expenditures in unadjusted descriptive models, it was not among the top 10 predictors.</p><p><strong>Conclusion: </strong>Among older adults with MCC, cardiac and renal conditions were the leading drivers of total expenditures and OOP expenditures. Our findings suggest that managing cardiac and renal conditions may be important for cost containment efforts.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"847-868"},"PeriodicalIF":2.1,"publicationDate":"2024-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11646392/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142830367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioral Economic Strategies Increase Adverse Event Reporting in Pediatric Anesthesia. 行为经济策略增加儿科麻醉不良事件报告。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-12-07 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S499363
Tiffany K Guan, Brittany L Willer, Jack Stevens, Joseph D Tobias, Vanessa A Olbrecht
{"title":"Behavioral Economic Strategies Increase Adverse Event Reporting in Pediatric Anesthesia.","authors":"Tiffany K Guan, Brittany L Willer, Jack Stevens, Joseph D Tobias, Vanessa A Olbrecht","doi":"10.2147/CEOR.S499363","DOIUrl":"10.2147/CEOR.S499363","url":null,"abstract":"<p><strong>Introduction: </strong>Identification and reporting of severe adverse events (SAEs) during anesthesia care remains critical in identifying areas of improvement in perioperative patient care. Although many healthcare organizations rely on the self-reporting of SAEs, under-reporting may limit the identification of the true incidence of these events. To circumvent these barriers, many healthcare systems leverage the Electronic Medical Record (EMR) by incorporating an Anesthesia Information Management System (AIMS).</p><p><strong>Methods: </strong>We followed the Institute for Healthcare Improvement's Model of Improvement and implemented behavioral economic-based interventions to our perioperative practice including adding a deliberation-promoting \"hard stop\" that required the anesthesiologists to report the occurrence or absence of a \"notable event\" prior to closing a patient's encounter in the EMR system.</p><p><strong>Results: </strong>At baseline, 53% of SAEs were self-reported. The interventions resulted in a baseline shift to more than 75% self-reporting, a relative increase of 42%.</p><p><strong>Conclusion: </strong>An increase in reporting of SAEs was achieved with simple interventions including modifications of the EMR which were done with limited financial impact or interruption in the work flow.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"841-845"},"PeriodicalIF":2.1,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11635159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142819767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluating Service Satisfaction and Sustainability of the Afya Health Insurance Scheme in Kuwait: An Exploratory Analysis [Response to Letter]. 评估科威特 Afya 健康保险计划的服务满意度和可持续性:探索性分析[回信]。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-11-21 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S504544
Maha Alnashmi, Nuzhat Masud Bhuiyan, Nour AlFaham, Ahmad Salman, Hanadi AlHumaidi, Nabeel Akhtar
{"title":"Evaluating Service Satisfaction and Sustainability of the Afya Health Insurance Scheme in Kuwait: An Exploratory Analysis [Response to Letter].","authors":"Maha Alnashmi, Nuzhat Masud Bhuiyan, Nour AlFaham, Ahmad Salman, Hanadi AlHumaidi, Nabeel Akhtar","doi":"10.2147/CEOR.S504544","DOIUrl":"10.2147/CEOR.S504544","url":null,"abstract":"","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"839-840"},"PeriodicalIF":2.1,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11587808/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142716643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characteristics of High-Cost Beneficiaries of Prescription Drugs in Kazakhstan: A Cross-Sectional Study of Outpatient Data from 2022. 哈萨克斯坦处方药高成本受益人的特征:对 2022 年门诊数据的横断面研究》。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-11-13 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S470632
Adilet Nazarbayev, Ardak Nurbakyt, Bibigul Omirbayeva, Anuar Akhmetzhan, Lyazzat Kosherbayeva
{"title":"Characteristics of High-Cost Beneficiaries of Prescription Drugs in Kazakhstan: A Cross-Sectional Study of Outpatient Data from 2022.","authors":"Adilet Nazarbayev, Ardak Nurbakyt, Bibigul Omirbayeva, Anuar Akhmetzhan, Lyazzat Kosherbayeva","doi":"10.2147/CEOR.S470632","DOIUrl":"10.2147/CEOR.S470632","url":null,"abstract":"<p><strong>Background and objectives: </strong>Limited information is available regarding the distribution of increasing pharmaceutical expenditures within large representative samples of national populations globally. The aim was to investigate the distribution of pharmaceutical costs in outpatient treatment and analyze the primary characteristics of users of expensive drugs within the healthcare system of Kazakhstan.</p><p><strong>Methods: </strong>This study utilized data from the Information System for Outpatient Drug Supply, which includes nationally representative data from all regions of Kazakhstan, covering both rural and urban populations. The key explanatory variables in this study included age, gender, number of prescribed medications, disease categories based on ICD-10 codes, and insurance coverage status. These variables were selected to capture demographic, clinical, and healthcare access factors influencing prescription drug costs. In total, 2.2 million people, who were prescribed outpatient medications were included. High-cost users (HCUs) were characterized as individuals whose prescription drug expenses ranked within the highest 5%.</p><p><strong>Results: </strong>The distribution of pharmaceutical costs exhibits significant discrepancy, with 5% of the population receiving prescription drugs covered by the state budget and social medical insurance fund contributing to nearly three-quarters of all costs. Notably, these HCUs tended to be younger than low-cost drug users. HCUs, on average, consumed a greater quantity of medications compared to non-HCUs. Among children, the top diseases contributing to high costs were rare hereditary diseases and malignancies, while in adults, cancer and diabetes were the primary cost drivers.</p><p><strong>Conclusion: </strong>There is a concentration of public drug program spending within a small percentage of beneficiaries with high drug costs in Kazakhstan. This discovery offers valuable insights for shaping policies tailored to this specific population, aiming to mitigate escalating costs and enhance the optimal use of medications.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"827-837"},"PeriodicalIF":2.1,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11572462/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142669320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost Analysis of Thromboprophylaxis in Patients at High Thromboembolic Risk with Enoxaparin, Dalteparin and Nadroparin in Colombia: A Systematic Literature Review-Based Study. 哥伦比亚血栓栓塞高危患者使用依诺肝素、达尔肝素和纳多肝素进行血栓预防的成本分析:基于文献综述的系统性研究。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-11-08 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S472192
Jose Rojas-Suarez, Juan Camilo Gutiérrez Clavijo, Josefina Zakzuk, Juan-Felipe López, Liliana Silva Gomez, Sergio Londoño Gutiérrez, Nelson J Alvis-Zakzuk
{"title":"Cost Analysis of Thromboprophylaxis in Patients at High Thromboembolic Risk with Enoxaparin, Dalteparin and Nadroparin in Colombia: A Systematic Literature Review-Based Study.","authors":"Jose Rojas-Suarez, Juan Camilo Gutiérrez Clavijo, Josefina Zakzuk, Juan-Felipe López, Liliana Silva Gomez, Sergio Londoño Gutiérrez, Nelson J Alvis-Zakzuk","doi":"10.2147/CEOR.S472192","DOIUrl":"https://doi.org/10.2147/CEOR.S472192","url":null,"abstract":"<p><strong>Purpose: </strong>To analyze the costs of high thromboembolic risk patients who require low molecular weight heparins (LMWHs) as a thromboprophylaxis strategy.</p><p><strong>Methods: </strong>Cost analysis was conducted to assess LMWHs (enoxaparin versus comparators: nadroparin and dalteparin) as thromboprophylaxis for hospitalized patients with high thromboembolic risk in Oncology, General or Orthopedic Surgery, and Internal Medicine services from the healthcare provider's perspective in Colombia. A decision tree was developed, and the health outcomes considered in the analysis were deep vein thrombosis, major bleeding, pulmonary thromboembolism, and chronic pulmonary hypertension. Clinical inputs were obtained from a systematic review of the literature and the economic parameters from micro-costing. Inputs were validated by three clinical experts. Costs were expressed in 2020 US dollars (USD).</p><p><strong>Results: </strong>In a hypothetical cohort of 10,000 patients with a thromboprophylaxis use rate of 40%, the use of enoxaparin was less costly than that of dalteparin in Oncology (difference of USD 624,669), Orthopedic Surgery (difference of USD 275,829), and Internal Medicine (difference of USD 109,119) patients. For these services, using enoxaparin was more efficient than using nadroparin (cost differences of USD 654,069, USD 416,927, and USD 92,070, respectively). Sensitivity analysis showed an important influence of the number of patients undergoing thromboprophylaxis, as well as the unit cost, and the risk of events (DVT, PTE, and CTEPH).</p><p><strong>Conclusion: </strong>Enoxaparin is the least expensive health technology for thromboprophylaxis in most of the medical contexts analyzed in Colombia due to its efficacy and the lower risk of complications than dalteparin and nadroparin.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"813-825"},"PeriodicalIF":2.1,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective. 从意大利国家医疗服务体系的角度对每周一次的伊科达克胰岛素进行经济评估。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S475461
Enrico Torre, Sergio Di Matteo, Giacomo Matteo Bruno, Chiara Martinotti, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo
{"title":"Economic Evaluation of Once-Weekly Insulin Icodec from Italian NHS Perspective.","authors":"Enrico Torre, Sergio Di Matteo, Giacomo Matteo Bruno, Chiara Martinotti, Luigi Carlo Bottaro, Giorgio Lorenzo Colombo","doi":"10.2147/CEOR.S475461","DOIUrl":"https://doi.org/10.2147/CEOR.S475461","url":null,"abstract":"<p><strong>Background: </strong>Icodec, once-weekly basal insulin, aims to simplify therapy management by reducing injection frequency for diabetic patients. The efficacy and safety of icodec were evaluated in the ONWARDS clinical development program. This study evaluates icodec economic and quality of life impact from the Italian National Healthcare System (NHS) perspective.</p><p><strong>Materials and methods: </strong>A pharmacoeconomic study was developed to assess the once-weekly insulin icodec value, highlighting its potential to decrease needle use while improving adherence and quality of life. In the base case, a differential cost and cost-utility analysis over one year compared to once-daily insulin degludec were developed. Based on the comparison with degludec, a scenario analysis was planned between icodec and the mix of basal insulins available on the market. Economic evaluations included drug and administration costs, needles, and impact on adherence. The cost-utility analysis measured the utility associated with the weekly injection compared to the daily ones, resulting in an incremental cost-effectiveness ratio (ICER), measured as Δ€/ΔQALY (Quality Adjusted Life Years). To assess the robustness of the results, a deterministic one-way sensitivity analysis and a probabilistic sensitivity analysis were carried out.</p><p><strong>Results: </strong>At an annual cost 25% higher than degludec, considering the economic benefits generated by the needle use reduction (-€51.10) and adherence improvement (-€54.85), once-weekly icodec grants no incremental cost and even potential savings per patient. Furthermore, icodec reported a utility advantage (0.023). It achieved a dominant incremental cost-effectiveness ratio (ICER) compared to degludec. The comparison with the mix of basal insulins also reported a cost-effectiveness profile. Sensitivity tests conducted confirmed the robustness of the findings, highlighting the key drivers of the analysis.</p><p><strong>Conclusion: </strong>Icodec represents a new therapeutic option to simplify basal insulin treatment. It also improves the patient's management and his quality of life, without increasing the economic burden for the Italian NHS, while guaranteeing an excellent cost-effectiveness profile.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"799-811"},"PeriodicalIF":2.1,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11550686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Utility of Real-Time Continuous Glucose Monitoring versus Self-Monitoring of Blood Glucose in People with Insulin-Treated Type 2 Diabetes in Spain. 西班牙胰岛素治疗 2 型糖尿病患者的实时连续血糖监测与自我血糖监测的成本效益比较。
IF 2.1
ClinicoEconomics and Outcomes Research Pub Date : 2024-11-05 eCollection Date: 2024-01-01 DOI: 10.2147/CEOR.S483459
Juan Francisco Merino-Torres, Sabrina Ilham, Hamza Alshannaq, Richard F Pollock, Waqas Ahmed, Gregory J Norman
{"title":"Cost-Utility of Real-Time Continuous Glucose Monitoring versus Self-Monitoring of Blood Glucose in People with Insulin-Treated Type 2 Diabetes in Spain.","authors":"Juan Francisco Merino-Torres, Sabrina Ilham, Hamza Alshannaq, Richard F Pollock, Waqas Ahmed, Gregory J Norman","doi":"10.2147/CEOR.S483459","DOIUrl":"https://doi.org/10.2147/CEOR.S483459","url":null,"abstract":"<p><strong>Objective: </strong>Management of advanced type 2 diabetes (T2D) typically involves daily insulin therapy alongside frequent blood glucose monitoring, as treatments such as oral antidiabetic agents are therapeutically insufficient. Real-time continuous glucose monitoring (rt-CGM) has been shown to facilitate greater reductions in glycated hemoglobin (HbA1c) levels and improvements in patient satisfaction relative to self-monitoring of blood glucose (SMBG). This study aimed to investigate the cost-utility of rt-CGM versus SMBG in Spanish patients with insulin-treated T2D..</p><p><strong>Methods: </strong>The analysis was conducted using the IQVIA Core Diabetes Model (CDM V9.5). Baseline characteristics of the simulated patient cohort and treatment efficacy data were sourced from a large-scale, United States-based retrospective cohort study. Costs were obtained from Spanish sources and inflated to 2022 Euros (EUR) where required. A remaining lifetime horizon (maximum 50 years) was used, alongside an annual discount rate of 3% for future costs and health effects. A willingness-to-pay (WTP) threshold of EUR 30,000 per quality-adjusted life year (QALY) was adopted, based on precedent across previous cost-effectiveness studies set in Spain. A Spanish payer perspective was adopted.</p><p><strong>Results: </strong>Over patient lifetimes, rt-CGM yielded 9.933 QALYs, versus 8.997 QALYs with SMBG, corresponding to a 0.937 QALY gain with rt-CGM. Total costs in the rt-CGM arm were EUR 2347 higher with rt-CGM versus SMBG (EUR 125,365 versus EUR 123,017). The base case incremental cost-utility ratio was therefore EUR 2506 per QALY gained, substantially lower than the WTP threshold of EUR 30,000 per QALY. The analysis also projected a reduction in cumulative incidence of ophthalmic, renal, neurological, and cardiovascular events in rt-CGM users, with reductions of 16.03%, 13.07%, 7.34%, and 9.09%, respectively.</p><p><strong>Conclusion: </strong>Compared to SMBG, rt-CGM is highly likely to be a cost-effective intervention for patients living with insulin-treated T2D in Spain.</p>","PeriodicalId":47313,"journal":{"name":"ClinicoEconomics and Outcomes Research","volume":"16 ","pages":"785-797"},"PeriodicalIF":2.1,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11549913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信